bioRxiv Science⌕ Search

Biology subjects

Bora, N.

Publications and source records attributed to Bora, N..

2 recordsLinked to original sources

Pervasive ancestry bias in variant effect predictors

Variant effect predictors (VEPs) - computational tools that assess the potential impact of genetic variants - have become increasingly vital for clinical variant interpretation. Currently, most VEPs used in variant prioritisation have been trained on datasets of clinically curated or population-derived variants. These datasets, however, disproportionately represent individuals of European descent. We hypothesised that this bias may lead to unequal VEP performance across different populations. To test this, we evaluated the scoring patterns of 52 VEPs for missense variants across 14 ancestry groups. We observe striking disparities: some VEPs predict a markedly higher proportion of damaging variants in underrepresented populations, such as those of Malay descent, compared to individuals of European ancestry. In contrast, VEPs that do not rely on clinical or population data predict more consistent pathogenicity burdens across ancestry groups. Moreover, we could closely link these discrepancies across methods to biases in training data. Our findings underscore the urgent need to adopt tools that minimise ancestry bias to ensure fairer and more accurate variant effect prediction and genetic diagnoses for all populations.

bioinformatics↗

Delivering on the Vision of Bench to Bedside: A Rare Disease Funding Community Collaboration to Develop Effective Therapies for Neurofibromatosis Type 1 Tumors

The time from target identification to new drug approval is often measured in decades. This can be even more challenging for rare diseases. Indeed, 95% of rare diseases do not have a specific therapy approved. Coordinated efforts to support research along the drug development pipeline can provide long term and comprehensive support to enable scientific breakthroughs for rare diseases. However, this requires coordination across multiple stakeholders. The present article analyzes the funding efforts of four major federal and philanthropic organizations to accelerate the advancement of MEK inhibitors to human clinical trials for NF1-associated tumors.

scientific communication and education↗